Vcanbio Cell & Gene Engineering Corp., Ltd. Class ASSE: 600645

Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection

· Issued by Vcanbio Cell & Gene Engineering Corp., Ltd. Class A via Shanghai Stock Exchange
Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Earlier from Vcanbio Cell & Gene Engineering Corp., Ltd. Class A

All Vcanbio Cell & Gene Engineering Corp., Ltd. Class A news releases